The next goal of preclinical and clinical research is to find reasonable combinations of PD-1/PD-L1 blockade and other treatments to reduce toxic side effects, exert stronger anti-tumor immune responses and precisely kill cancer cells, so that cancer can become a type of curable chronic disease. The gene discussed is CD274; the disease is cancer.